ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Shigefumi Suehiro
Toshihiko Shibata
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumano, H.
Right arrow Articles by Kinoshita, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumano, H.
Right arrow Articles by Kinoshita, H.

Ann Thorac Surg 1999;68:1252-1256
© 1999 The Society of Thoracic Surgeons


Original Articles

Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization

Hiroshi Kumano, MD, PhDa, Shigefumi Suehiro, MD, PhDa, Koji Hattori, MD, PhDa, Toshihiko Shibata, MD, PhDa, Yasuyuki Sasaki, MDa, Mitsuharu Hosono, MDa, Hiroaki Kinoshita, MD, PhDa

a Second Department of Surgery, Osaka City University Medical School, Osaka, Japan

Address reprint requests to Dr Kumano, Second Department of Surgery, Osaka City University Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan

Background. We examined the safety of reduced systemic heparinization during heparin-coated cardiopulmonary bypass by measuring coagulofibrinolitic indices, including fibrinopeptide A, which directly reflects fibrinogenesis.

Methods. Twenty-four patients who had elective cardiac operations were perfused using a circuit coated with covalently bonded heparin. Twelve patients received 300 U/kg of heparin and the remaining 12 patients received 150 U/kg. Blood was obtained for the measurement of thrombin-antithrombin III complexes, fibrinopeptide A, plasmin-alpha 2 plasmin inhibitor complexes, and D-dimer preoperatively; after heparin administration; 10, 60, and 90 minutes after the start of bypass; after protamine administration; and 1, 3, 6, 12, and 24 hours after the end of bypass.

Results. Preoperative, intraoperative, and postoperative variables including postoperative bleeding were not significantly different between the two groups. Further, there were no complications in either group. No significant differences between the two groups were noted for any hematologic index at any time point.

Conclusions. Reduced systemic heparinization combined with a heparin-coated cardiopulmonary bypass circuit is biochemically and clinically safe but does not reduce postoperative bleeding.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
R. D. Frank, U. Muller, R. Lanzmich, C. Groeger, and J. Floege
Anticoagulant-free Genius(R) haemodialysis using low molecular weight heparin-coated circuits
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 1013 - 1018.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. Fujii, S. Suehiro, H. Kumano, T. Shibata, K. Hattori, H. Hirai, and T. Aoyama
Relationship between granulocyte elastase and C3a under protamine dosing in on-pump cardiac surgery
Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 431 - 434.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Ikuta, H. Fujii, T. Shibata, K. Hattori, H. Hirai, H. Kumano, and S. Suehiro
A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy
Ann. Thorac. Surg., May 1, 2004; 77(5): 1678 - 1683.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Shibata, Y. Sasaki, K. Hattori, H. Hirai, M. Hosono, H. Fujii, and S. Suehiro
Sonoclot analysis in cardiac surgery in dialysis-dependent patients
Ann. Thorac. Surg., January 1, 2004; 77(1): 220 - 225.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Johnell, G. Elgue, R. Larsson, A. Larsson, S. Thelin, and A. Siegbahn
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface
J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 321 - 332.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
D. Paparella, T.M. Yau, and E. Young
Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update
Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 232 - 244.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.